Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Want to see LEGN full AI Analyst Report?
LEGN Stock Chart & Stats
$21.17
-$0.50(-1.49%)
At close: 4:00 PM EST
$21.17
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$16.24 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)2.52M
Market Cap
$5.04B
Enterprise Value$4.77B
Total Cash (Recent Filing)$834.63M
Total Debt (Recent Filing)$389.31M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 18, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding185,739,790
10 Day Avg. Volume1,652,572
30 Day Avg. Volume2,521,738
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)4.00
Price to Sales (P/S)3.89
P/FCF Ratio-23.85
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue4.18
Enterprise Value/Gross Profit7.61
Enterprise Value/Ebitda-26.32
Forecast
1Y Price Target
$55.90Price Target Upside164.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.09
Revenue Forecast (FY)$1.43B
Bulls Say, Bears Say
Bulls Say
Rapid CARVYKTI Revenue ScalingSustained, high-single- to double-digit sales growth for CARVYKTI shows durable commercial adoption and expanding addressable market. Persistent revenue scale supports gross-profit leverage, funds R&D and manufacturing buildout, and underpins a multi-quarter path toward company-level adjusted profitability.
High Manufacturing ReliabilityNear-perfect manufacturing yield and fast turnaround materially reduce supply bottlenecks for a complex autologous CAR‑T product. Reliable supply enables broader clinic access, faster patient throughput and supports earlier-line adoption—key structural enablers of durable revenue and margins over multiple quarters.
Strong Liquidity With No Long-term DebtA large cash balance and absence of long-term debt provide financial flexibility to fund commercialization, manufacturing scale-up and early-stage programs without immediate refinancing. This reduces short-to-mid-term solvency risk and supports execution through pivotal readouts and IND filings.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn to support commercialization and pipeline work. Even with current cash, continued FCF deficits risk future dilution or need for financing if profitability timing slips, pressuring long-term capital efficiency and shareholder returns.
Continued Losses And Negative Returns On EquityDespite revenue scale, the company remains loss-making with materially negative net margins and ROE, meaning shareholder capital isn’t yet producing profits. Sustained negative profitability can limit reinvestment capacity and prolong reliance on partners or capital markets absent durable margin improvement.
Event-driven Clinical Timing RiskLabel expansion and meaningful market-share gains depend on event-driven pivotal readouts with uncertain timing. Delays or adverse outcomes would slow earlier-line uptake and associated revenue milestones, creating structural uncertainty around the company’s multi-year growth trajectory and commercial upside.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $16.24 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $5.04B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 18, 2026 which is in 76 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.162.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is 0.07.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 185,739,790 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.15 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went up 10.477%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.90 (164.06% Upside)
$55.90 (164.06% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $87.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.88%
12-Months-Change
Fundamentals
Return on Equity
-24.91%
Trailing 12-Months
Asset Growth
-1.17%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
LEGN Company Deck
LEGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and operational performance—notably robust CARVYKTI sales growth (52% YoY), improved manufacturing metrics (99% success, 29-day turnaround), deeper earlier-line penetration (41% vs 29% YoY), a solid cash position (~$835M), and a clear path to adjusted profitability in 2026. These positives are tempered by a near-term gross margin hit (41% vs 57% prior quarter) from one-time manufacturing ramp costs, an adjusted net loss still present in Q1, event-driven uncertainty around pivotal readouts (CARTITUDE-5/6), and early-stage clinical risk for the In Vivo programs where safety/efficacy data are not yet disclosed. On balance, the highlights (strong growth, manufacturing execution, expanding pipeline, balance sheet strength, path to profitability) outweigh the lowlights, supporting a constructive view of the company's near- to mid-term outlook.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$55.90
▲(164.06% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.13% Insiders
14.15% Mutual Funds
23.37% Other Institutional Investors
59.34% Public Companies and
Individual Investors